Searchable abstracts of presentations at key conferences in endocrinology

ea0031p160 | Neoplasia, cancer and late effects | SFEBES2013

Adjuvant use of 131I-MIBG in phaeochromocytoma and paraganglioma at high risk of malignancy

Rutherford Matthew A , Rankin Alastair , Yates Michael , Reed Nicholas , Freel E Marie

Phaeochromocytomas (Phaeo) and paragangliomas (PGL) are rare catecholamine producing tumours. It can be difficult to predict their malignant potential and patients can sometimes present with metastatic disease many years after their original diagnosis (1). Therefore, we offer a single dose of adjuvant 131I-Metaiodobenzylguanidine (131I-MIBG) to subjects felt to be at higher risk of local recurrence (demonstration of capsular or vascular invasion on pathol...

ea0025p178 | Endocrine tumours and neoplasia | SFEBES2011

Metastatic insulinoma treated by transhepatic arterial embolisation

Freel E Marie , McDougall Claire , Campbell Karen , Grant Donna , Kasthuri Ram , Reed Nicholas

A 64-year-old man (HM) was admitted to our local hospital with transient dysarthria and right hemiparesis; formal blood glucose was 2.2 mmol/l on admission. During his in-patient stay, he had frequent episodes of hypoglycaemia. Further questioning revealed a 4 week history of recurring dizzy spells which improved on eating.Cerebral imaging and adrenal function were normal and so the patient underwent further investigations (summarised below) which confir...

ea0052oc3 | (1) | UKINETS2017

Incidence and prevalence of neuroendocrine tumours in England

Genus Tracey , Bouvier Catherine , Wong Kwok , Srirajaskanthan Rajaventhan , Rous Brian , Talbot Denis , Valle Juan , Khan Mohid , Pearce Neil , Elshafie Mona , Reed Nicholas , Luong Tu Vinh , Munir Alia , Ramage John

Introduction: Historically the incidence and prevalence of neuroendocrine tumours (NETs) has been difficult to establish due to issues with disease coding and data collection. Studies estimated the incidence of gastroenteropancreatic neuroendocrine tumours (GEP NETs) to be 1.3 per 100,000 per year (incidence hereafter given as cases per 100,000). However, the SEER USA data suggests a four-fold higher incidence, and prevalence of 35 per 100,000. This study aimed to identify the...

ea0052p12 | (1) | UKINETS2017

1-Year survival rates for neuroendocrine tumour patients in England

Genus Tracey , Bouvier Catherine , Wong Kwok , Srirajaskanthan Rajaventhan , Rous Brian , Talbot Denis , Valle Juan , Khan Mohid , Pearce Neil , Elshafie Mona , Reed Nicholas , Luong Tu Vinh , Munir Alia , Ramage John

Introduction: Accurate survival data for patients with neuroendocrine tumours (NETs) across the UK has been difficult to capture. Individual centres often report good survival rates, however, national data has not previously been available.Materials and methods: NET patient survival was calculated for England using the Public Health England (PHE) National Cancer Registration and Analysis Service (NCRAS) dataset which captures tumour stage using TNM stagi...

ea0052p13 | (1) | UKINETS2017

Metachronous primary cancers in neuroendocrine tumour patients

Genus Tracey , Bouvier Catherine , Wong Kwok , Srirajaskanthan Rajaventhan , Rous Brian , Talbot Denis , Valle Juan , Khan Mohid , Pearce Neil , Elshafie Mona , Reed Nicholas , Luong Tu Vinh , Munir Alia , Ramage John

Introduction: Historically there has been an association with neuroendocrine tumours (NETs) and other cancers. However, this has not previously been well characterised. We aimed to determine the incidence of second malignancies in patients with NETs and investigate any association of the anatomical site of NETs with other malignancies.Materials and methods: 12,844 patients were diagnosed with a NET between 2013 and 2015 and captured by the National Cance...